Maintaining a Hold: Solid Execution at Amicus but Limited Upside Ahead of the BioMarin Acquisition

Needham analyst Gil Blum has maintained their neutral stance on FOLD stock, giving a Hold rating on February 21.

Gil Blum has given his Hold rating due to a combination of factors, including solid but largely anticipated commercial execution and the pending BioMarin acquisition. Amicus delivered full-year 2025 revenue growth of about 20%, with Galafold slightly outperforming consensus and the newer Pompe therapy tracking in line with prior management targets, while the company also sustained marginal GAAP profitability and exited the year with a strong cash balance.

However, the lack of forward financial guidance, tied to expectations that the BioMarin transaction will close in the second half of 2026, limits near‑term visibility for standalone valuation. In addition, Blum does not foresee a competitive bidding process emerging around Amicus, which in his view caps upside potential from strategic interest and supports maintaining a neutral, Hold stance on the shares.

In another report released on February 21, TipRanks – OpenAI also downgraded the stock to a Hold with a $15.00 price target.

Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FOLD in relation to earlier this year.